Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Abalone Bio aims to develop innovative obesity treatment drugs by targeting metabolic GPCRs, addressing current limitations in weight loss therapies and meeting unmet clinical needs globally [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a formal cooperation agreement with Abalone Bio to jointly advance the research and development of next-generation obesity treatment drugs [1] - The project focuses on enhancing energy expenditure safely and effectively while maintaining or increasing muscle mass, which is a significant challenge in current weight loss therapies [1] Group 2: Technical and Strategic Aspects - Abalone Bio will provide its core technology and platform support in GPCR antibody discovery, while Four Seasons will contribute its research and development resources in metabolic diseases and its established business framework in Greater China [2] - The collaboration is built on a prior strategic investment made by Four Seasons in Abalone earlier this year, marking a transition from capital investment to business execution [2] Group 3: Market Positioning and Future Prospects - This partnership strengthens Four Seasons' innovative positioning in the weight loss sector and accelerates the development of new weight loss and muscle gain therapies [2] - The collaboration is also a strategic move to deepen Four Seasons' involvement in the GPCR target area, following its investment in DJS Antibodies, which focuses on GPCR-targeted antibodies [2]